CD8A and hepatocellular carcinoma: By applying peptide/MHCI tetramer-based enrichment, we characterized circulating TAA-specific CD8+ T cells targeting gylpican-3, NY-ESO-1, MAGE-A1, and MAGE-A3 in therapy-naïve HCC patients [102].